DuPont's diversified turnover up 9%:
This article was originally published in Clinica
US conglomerate DuPont has reported 9% growth in revenues for its diversified businesses to $3,339 million in the first half of the year. This division includes DuPont's imaging and diagnostics operations which were put up for sale in May (see Clinica No 656, p 11). Dupont's total first-half sales increased 12% to $21,578 million and net income rose 32% to $1,897 million.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.